Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | June 10, 2025 | June 12, 2025 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director · President and CEO | October 19, 2021 | October 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date June 10, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.01 · Expires 2035-06-09 | Direct | 19,000 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
vTv Therapeutics Inc.
Report date October 19, 2021 · Filed October 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2031-10-19 | Direct | 2,498,635 |
Reported balance
After 2021-10-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-19 · Grant · Acquired 2,498,635 · Balance 2,498,635 F1: Options were granted as part of an inducement award and will vest on October 19, 2024 subject to continued employment (or earlier, upon achievement of certain performance measures). |
Filing footnotes · ownership attribution and instrument terms
F1: Options were granted as part of an inducement award and will vest on October 19, 2024 subject to continued employment (or earlier, upon achievement of certain performance measures).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001415889-25-016957 · form4-06122025_040608.xml · derivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 23:30 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 3,806 | $6.27 | $23,863.62 |
DisclosureSEC source: 0001415889-24-029913 · form4-12192024_061201.xml · nonDerivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001415889-24-017237 · form4-06172024_050611.xml · derivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 13, 2024 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 22:06 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 12,000 | $2.31 | $27,669.60 |
DisclosureSEC source: 0001209191-23-047774 · doc4.xml · nonDerivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,806 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.29 to $2.31, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth herein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001209191-23-033787 · doc4.xml · derivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:06 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001209191-22-037509 · doc4.xml · derivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 21:37 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | OtherCommon Stock | 11,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020082 · doc4.xml · nonDerivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,806 F1 · kind: In-kind distribution from WRG HCD1, LLC of which the reporting person is a member. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:38 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 2,498,635 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0000950142-21-003262 · es210194007_4-prasad.xml · derivative · entry 1 Prasad Deepa · CIK 0001867165 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,498,635 Underlying: Class A common stock · 2,498,635 shares Expires 2031-10-19 F1 · derivative.exercise_date: Options were granted as part of an inducement award and will vest on October 19, 2024 subject to continued employment (or earlier, upon achievement of certain performance measures). Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:21 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $27.04 | $0.00 |
DisclosureSEC source: 0001209191-21-040998 · doc4.xml · derivative · entry 1 Prasad Deepa · CIK 0001867165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a three year period following June 15, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.